Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

(2011) Wieslawa H Dragowska et al.   BMC CANCER

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo

(2011) Cheng-Xiong Xu et al.   PLoS One

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

(2010) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

(2010) Merel Gijsen et al.   PLOS BIOLOGY

Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer

(2009) C. Shah et al.   CLINICAL CANCER RESEARCH

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

(2009) T. W. Miller et al.   CLINICAL CANCER RESEARCH

Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

(2009) A. Magnifico et al.   CLINICAL CANCER RESEARCH

Inhibitor hijacking of Akt activation

(2009) Tatsuya Okuzumi et al.   Nature Chemical Biology

Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53-Mediated Mouse Mammary Tumors

(2008) N. Shafee et al.   CANCER RESEARCH

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

(2008) Paolo Baldo et al.   CURRENT CANCER DRUG TARGETS